Cancer Network Staff

Data from the phase 3 OptiTROP-Lung06 trial also showed a positive trend in overall survival with sac-TMT plus pembrolizumab in patients with NSCLC.

The FDA closed out its manufacturing inspection tied to the third complete response letter for rivoceranib/camrelizumab in unresectable HCC.

The FDA has approved the gedatolisib combination for HR+/HER2– PIK3CA wild-type advanced breast cancer post-CDK4/6i, based on the phase 3 VIKTORIA-1 trial.

Agenus is halting financial support for the phase 3 BATTMAN trial in late-line metastatic MSS colorectal cancer to prioritize neoadjuvant development of the same regimen.

Data from the phase 2 RECLAIM trial demonstrate the feasibility of a multimodal strategy in a patient population with limited therapeutic options.

Interim data from the phase 2 AZUR-1 trial showed sustained clinical complete responses with dostarlimab monotherapy in dMMR/MSI-H locally advanced rectal cancer.

The trial will confirm findings from the phase 3 IT-MATTERS study subgroup with newly diagnosed head and neck cancer who received leukocyte interleukin.

The approval of Orca-T validates many years of work dedicated to manipulating the graft to improve outcomes among patients undergoing allogeneic transplant.

ARTEMIS-008 is the first phase 3 trial to show positive overall survival data for a B7-H3–targeted antibody-drug conjugate in any tumor type.

The FDA has issued a third CRL for the combination based on manufacturing site deficiencies associated with the new drug application.

Miguel A. Materin, MD, discussed insights on multidisciplinary care, intra-arterial chemotherapy, and the evolving landscape of uveal melanoma treatments.

Ateganosine plus cemiplimab showed an acceptable safety profile among patients with third-line NSCLC in the phase 2 THIO-101 trial.

The European Medicines Agency has begun a phased review of daraxonrasib for pancreatic cancer as the FDA nears completion of a rolling new drug application submission.

Data from a phase 2 trial show the potential of inotuzumab ozogamicin to deepen remissions in patients with B-cell acute lymphoblastic leukemia.

Catch up on key data in colorectal, pancreatic, and hepatocellular cancers presented at the ESMO Gastrointestinal Cancers Congress 2026.

The European Commission approved epcoritamab/R2 for adult patients with relapsed/refractory follicular lymphoma based on the phase 3 EPCORE FL-1 data.

The FDA declined to approve Orviglance for MRI liver imaging in patients with severe kidney impairment, requesting additional clinical data.

Paul G. Richardson, MD; and Muhamed Baljevic, MD, FACP, discussed the mechanism, synergy, tolerability, and sequencing of CELMoDs in multiple myeloma.

A molecular residual disease test identified which patients with resected colorectal liver metastases gained a survival benefit from adjuvant chemotherapy.

The RASolute 302 study of daraxonrasib was “the single biggest study presentation” at ASCO 2026, according to Sivraj Muralikrishnan, MD.

Experts focused on lymphoma cellular therapy convened to discuss CAR T-cell candidacy and practical barriers to access for patients with DLBCL.

Patients with clinically higher-risk disease but favorable GPS results had higher 6-year EFS rates across treatment arms vs those at a lower clinical risk.

FDA breakthrough designation and NCCN inclusion elevate Merlin CP-GEP as a tool to refine SLNB decisions in T1b/T2a melanoma, per MERLIN_001 trial data.

Updated phase 2a data showed durable survival in a small subset of heavily pretreated patients with advanced pancreatic cancer treated with namodenoson.

“[Epcoritamab/R2] is a good option for [patients] at first relapse or even further, even if they are very high risk,” said Benoit Tessoulin, MD, PhD.

The safety profile of epcoritamab when added to lenalidomide was consistent with the known profiles of each individual agent among this DLBCL population.

Teclistamab-based induction yielded a 100% overall response rate in transplant-eligible newly diagnosed multiple myeloma in the phase 2 MajesTEC-5 trial.

The CHMP recommended pirtobrutinib in chronic lymphocytic leukemia based on data from the phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials.

Experts map DLBCL CAR‑T from early referral and bridging therapy to managing CRS, ICANS, and survivorship challenges in community practice.

The tentative approval covers enzalutamide tablets in 4 doses—40 mg, 80 mg, 120 mg, and 160 mg—as a generic equivalent to the reference product.